Status: Recruiting
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.
Participants needed: 520
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Oct 13, 2026Locations: 2
Eligibility criteria
Histologically or cytologically documented metastatic or surgically unresectable... [+8]
Prior topoisomerase inhibitor-based ADC therapy. [+12]